TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01589419
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see arm description
Study: NCT02554045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
Study: NCT02716792
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
Study: NCT04331834
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months
Study: NCT01951105
Drug: Carbidopa/Levodopa
Normalized name: CARBIDOPA/LEVODOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period.
Study: NCT01951105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take two placebo capsules three times a day for 12 weeks.
Study: NCT03234842
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent weekly chemotherapy at standard doses
Study: NCT02261519
Drug: NaBen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice daily (1000 mg total)
Study: NCT00219635
Drug: UK-390,957
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02867332
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study: NCT03303521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Study: NCT01725087
Drug: Medium Dose GRT6005
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03204617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
Study: NCT01898052
Drug: single anaesthetic drug
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: inject periarticular tissue of the knee after implantation
Study: NCT01898052
Drug: multimodal drug injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: inject periarticular tissue of the knee
Study: NCT03905837
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous remifentanil
Study: NCT01520207
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
Study: NCT04472897
Drug: GSK2556286
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2556286 will be administered.
Study: NCT04472897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT00112918
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablets
Study: NCT00112918
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as a 200 mg/m\^2 infusion over 2 hours.
Study: NCT02964338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
Study: NCT01653457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
Study: NCT03952572
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m² ivgtt on day 1
Study: NCT03952572
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m² ivgtt on day 1
Study: NCT03952572
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m² ivgtt on day 1
Study: NCT04037514
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
Study: NCT02548052
Drug: GSK2981278 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
Study: NCT02548052
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
Study: NCT00237900
Drug: Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04057937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01247350
Drug: LY3009104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01247350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00122291
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027885
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT00027885
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT01007851
Drug: NaCl %0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml sterile saline sc injection 3 days after embryo transfer
Study: NCT00003494
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT05983328
Drug: HUYPS-1 nine tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
Study: NCT01651416
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01896193
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study: NCT01837251
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028507
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02633969
Drug: Indomethacin Capsules high dose
Normalized name: indomethacin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01750060
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02493452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00837967
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/4.5μg for 3 days
Study: NCT02446444
Drug: Conventional NSAA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04718480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po placebo tablets
Study: NCT00920959
Drug: FSC 100/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing
Study: NCT00920959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing
Study: NCT02716779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
Study: NCT00941304
Drug: Placebo Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo buccal film
Study: NCT00941304
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of oral placebo capsule
Study: NCT03311841
Drug: Atorvastatin and rosuvastatin oral solution
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
Study: NCT02992028
Drug: Intravenous Nutrition (Vitamins) injection
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02536105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01151345
Drug: TILACEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
Study: NCT03761134
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03761134
Drug: sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00028626
Drug: embolization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03249168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04044820
Drug: Standardized Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion.
Study: NCT00417157
Drug: recombinant FSH (Puregon, Organon, The Netherlands)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02574663
Drug: TGR-1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGR-1202 oral daily dose
Study: NCT02574663
Drug: Oxaliplatin + Folinic acid + Fluorouracil
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT02627573
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00437996
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04056949
Drug: IBI308
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
Study: NCT00139659
Drug: Inhaled Insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Study: NCT00139659
Drug: Subcutaneous Insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Study: NCT03215875
Drug: Fed- 60mg ER Torsemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg ER Torsemide will be given after high fat, high-calorie meal
Study: NCT04441788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by oral inhalation
Study: NCT00995722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
Study: NCT00441493
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00752999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, oral, twice-a-day
Study: NCT03868098
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (vehicle)
Study: NCT00301912
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00910871
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
Study: NCT00910871
Drug: Background Regimen (BR) for MDR-TB
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
Study: NCT01304953
Drug: Group P+P
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
Study: NCT01304953
Drug: Group P+T
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Study: NCT01304953
Drug: Group S+P
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
Study: NCT01304953
Drug: Group S+T
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Study: NCT04235426
Drug: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
Study: NCT02359552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01127048
Drug: Suppositories containing Ivy leaves dry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppositories containing Ivy leaves dry extract
Study: NCT01127048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppositories containing no Ivy leaves dry extract
Study: NCT02063594
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
Study: NCT01310127
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
Study: NCT01310127
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
Study: NCT03639857
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The topical corticosteroid will be used to treat the lesion in this study arm.
Study: NCT00024440
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03575247
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term use of glucocorticoids
Study: NCT02391571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 day placebo run in prior to test and active drug phase of study
Study: NCT00350077
Drug: Intravenous Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin C IV during 24 hour period following burn
Study: NCT00558012
Drug: Intravenous zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 5.0 mg once
Study: NCT03397121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT01005862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00856791
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00455000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04020653
Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
Study: NCT04020653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
Study: NCT04020653
Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
Study: NCT03872843
Drug: Norco 5milligram-325milligram Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
Study: NCT03872843
Drug: Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
Study: NCT02459197
Drug: Administration of Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment is given as add-on therapy to patient's regular analgesic treatment
Study: NCT03369314
Drug: octaplasLG®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data will be collected in all patients who have received at least one infusion of octaplasLG®
Study: NCT02785900
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
Study: NCT02710578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.